OncoMed Pharmaceuticals Inc: 10-Q filed 2015-08-10
What OncoMed Pharmaceuticals Inc reported in its quarterly report filed 2015-08-10 (fiscal Q2 2015): 24 published measures, 64 facts as tagged in accession 0001193125-15-284927.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-08-10
- Fiscal period
- fiscal Q2 2015
- Accession
- 0001193125-15-284927 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All OncoMed Pharmaceuticals Inc filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 209,081,000 | USD | |
| At 2014-12-31 | 247,842,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 162,770,000 | USD | |
| At 2014-12-31 | 171,475,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 46,311,000 | USD | |
| At 2014-12-31 | 76,367,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 36,255,000 | USD | |
| At 2014-12-31 | 28,138,000 | USD | |
| At 2014-06-30 | 23,379,000 | USD | |
| At 2013-12-31 | 208,931,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | -21,620,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -36,149,000 | USD | 181 |
| 2014-04-01 to 2014-06-30 | -15,597,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -29,468,000 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-06-30 | 1,035,000 | USD | 181 |
| 2014-01-01 to 2014-06-30 | 1,147,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | -260,585,000 | USD | |
| At 2014-12-31 | -224,436,000 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 12,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 23,000 | USD | 181 |
| 2014-04-01 to 2014-06-30 | 11,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 13,000 | USD | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 5,349,000 | USD | |
| At 2014-12-31 | 5,104,000 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | -21,635,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -36,175,000 | USD | 181 |
| 2014-04-01 to 2014-06-30 | -15,592,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -29,499,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 201,399,000 | USD | |
| At 2014-12-31 | 240,810,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 37,340,000 | USD | |
| At 2014-12-31 | 38,546,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 6,143,000 | USD | |
| At 2014-12-31 | 4,428,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 26,322,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 50,549,000 | USD | 181 |
| 2014-04-01 to 2014-06-30 | 21,607,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 41,529,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 22,045,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 41,478,000 | USD | 181 |
| 2014-04-01 to 2014-06-30 | 18,167,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 34,876,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 30,054,966 | shares | |
| At 2014-12-31 | 29,847,577 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 104,000 | USD | |
| At 2014-12-31 | -17,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 2,333,000 | USD | |
| At 2014-12-31 | 1,928,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 13,955,000 | USD | |
| At 2014-12-31 | 14,683,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-06-30 | 1,162,000 | USD | |
| At 2014-12-31 | 1,721,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | -21,591,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -36,028,000 | USD | 181 |
| 2014-04-01 to 2014-06-30 | -15,579,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -29,493,000 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-06-30 | 4,277,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 9,071,000 | USD | 181 |
| 2014-04-01 to 2014-06-30 | 3,440,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 6,653,000 | USD | 181 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-06-30 | 790,000 | USD | 181 |
| 2014-01-01 to 2014-06-30 | 685,000 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-06-30 | 1,708,000 | USD | 181 |
| 2014-01-01 to 2014-06-30 | -2,660,000 | USD | 181 |
Inspect the source
- Entity
- OncoMed Pharmaceuticals Inc / CIK 0001302573
- Captured
- SEC response SHA-256
a610277a1a1c3457a48919bb7f4183ca6e8fef7210f95869bd0b687e5f4fcca5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001302573.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))